SB-913-1603: A Phase I, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPS II)

Project: Research project

Project Details

StatusActive
Effective start/end date9/1/178/31/23

Funding

  • Sangamo Therapeutics, Inc.